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Previous attempts to develop an animal model of bullous 
pemphigoid (BP) have failed to result in inflammatory dis-
ease in the skin. Pl-2 is an lS-amino acid peptide encoded 
for by the 230-kD BP antigen cDNA that has been shown to 
contain an epitope recognized by circulating antibodies from 
patients with BP. The purpose of this study was to determine 
if ultraviolet B irradiation of rabbits after immunization with 
the Pl-2 peptide would result in an enhanced inflammatory 
response in the skin to that injury. Three rabbits were immu-
nized with either Pl-2 or a control peptide. All rabbits immu-
nized with Pl-2, and none of the control rabbits, developed 
antibodies against Pl-2 that bound ill vitro to both human and 
rabbit skin in a linear pattern at the basement membrane 
zone. Immunized rabbits were irradiated on the flank with 
ultraviolet light. Rabbits immunized with Pl-2 developed an 
Bullous pemphigoid (BP) is an autoimmune blistering disease characterized in part by the presence of immu-noglobulin (Ig) G antibodies directed against the epi-dermal basement membrane zone (BMZ) [1- 3]. IgG deposits are found in a linear band at the epidermal 
BMZ in up to 90% of patients with BP, whereas approximately 
70% have a circulating IgG that can bind to the BMZ of stratified 
squamous epithelium [1- 3]. The exact role this anti-BMZ antibody 
may play in the pathogenesis ofBP is not clear. Gammon el al have 
demonstrated in vitro that IgG from patients with BP can bind to 
normal human skin and activate complement, resulting in the mi-
gration and binding of neutrophils to the BMZ [4] . Circulating 
titers of antibody directed against the BMZ, however, correlate 
poorly with disease activity [5,6]. 
One method of characterizing the pathogenic role of the anti-
BMZ antibodies found in patients with BP would be to develop an 
animal model of the disease by the passive transfer of IgG from 
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enhanced inflammatory reaction to ultraviolet B irradiation 
leading to epidermal necrosis and sloughing of some sites in 
6 - 9 d. Control rabbits showed only mild erythema without 
sloughing, which healed in 4-6 d. Histology in the Pl-2 
immunized rabbits at 24 h revealed an inflammatory infil-
trate of neutrophils at the dermal-epidermal junction, 
whereas control rabbits showed only mild edema and a sparse 
inflammatory infiltrate. All the rabbits immunized with Pl-2 
had linear deposits of immunoglobulin G and C3 at the base-
ment membrane zone of healed skin compared to none of the 
controls. These findings demonstrate that antibodies against 
a synthetic peptide encoded by the BP antigen 1 sequence can 
lead to an enhanced inflammatory response after epithelial 
injury in rabbit skin.] Illvest Dermato[101:9-14, 1993 
patients with BP to animals. Such a model would allow for furth er 
investigation int.o the role ~f antibody as well as allow for the study 
of other factors Important 111 the development of skin lesions. Sev-
eral attempts to develop an animal model by passively transferring 
IgG from patients with BP to animals, however, have not been 
successful. Sams and Gleich transfused monkeys with plasma from 
three patients with BP and, although they did note some binding of 
IgG at the epidermal BMZ of the monkeys, the animals did not 
develop .any infian:matio.n in the s~in [7] . Maintenance of a high-
titer antl-BMZ antibody 111 these arumals was inhibited by the rapid 
development of monkey anti-human IgG antibodies. Naito and 
colleagues reported that the injection of sera from patients with BP 
into the skin of guin.ea pigs resultedin IgG and complement binding 
as well as dermal epidermal separation [8]. These findings however, 
could not be reproduced by Gammon and Briggaman [9]. Finally, 
Anhalt and co-workers utilized a rabbit model and demonstrated 
that IgG from patients with BP when directly injected into the 
cornea of rabbits resulted in the binding of IgG at the basement 
membrane zone, with polymorphonuclear leukocytes accumulat-
i~g at the BMZ and epithelial ~eparation from the stroma [10] . 
SI111Ultaneous experiments uSl11g I11tradermal injections of BP IgG, 
however, did not reveal any IgG binding at the epidermal BMZ or 
cutaneous inflammation [10]. These authors speculated that the 
slow clearance of human IgG from the cornea may allow for the 
binding ofIgG and development of pathologic changes that did not 
occur in the skin of the rabbits. 
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There are several potential explanations for the failur~ of these 
passive transfer experim~nts to elicit clinical eVidence .of sk111 disease 
in animals. One potenttal explanatIOn IS that the epidermis of the 
animals tested does not express the antigenic epitopes important 111 
BP. This seems unlikely because IgG from patients wit!1 BP ~an 
bind in vitro to the epidermal BMZ of all vertebrates, 111cludmg 
rabbits, guinea pigs, and monkeys, suggesting that these animals do 
not lack at least some of the antigenic sites present in the human BP 
antigen. In addition, DNA sequence analysis of the mouse 230~kd 
BP antigen has revealed greater than ~5% homolo~y at the ammo 
acid level with the human 230-kd antigen, suggest111g that the BP 
antigen has been relatively well conserved J11-13J. . 
Other potential explanatIOns for the failure of ~ass lve transfer 
experiments may he th~t human IgG may not persIst for long pe-
riods of time in the ammals used, that human IgG may not be an 
efficient activator of the inflammatory pathways in the animals 
used, or that the antigenic site may not be accessible to the circulat-
ing antibody in vivo. 
Recently we have demonstrated that approximately 37% of pa-
tients with BP have IgG antibody directed against an 18 -ammo 
acid synthetic peptide encoded by the cDNA for the 230-kD BP 
antigen [11,14, 15J. Rabbits immunized with this peptide ~eveloped 
an IgG antibody that bound in a linear pattern at the BMZ In nor~~l 
human skin by indirect immunofluorescence and immunopreclpl-
tated the human 230-kD BP antigen [15,16J. Rabbits with circulat-
ing antibody against Pl-2 did not develop any clinica l evidenc.e of 
skin disease or show binding ofIgG at the BMZ. We hypotheSized 
that mild, eidermal injury of animals that have a high-titer, circulat-
ing antibody directed against a cutaneous BMZ protein su.ch as 
encoded by Pl-2 could result in an inflammatory respon~e slmll~r to 
that seen in patients with BP. In this report we have Immumzed 
rabbits with an 18 -amino acid synthetic peptide encoded by the 
230-kD BP antigen cDNA and after demonstrating this presence of 
high-titer anti-BMZ antibody, exposed th.e animals to ul.travlOlet 
(UV) B irradiation. Animals immunized WIth the BP peptIde den:-
onstrated an enhanced inflammatory response, WIth resultant epI-
dermal necrosis and linear deposits of IgG and C3 at the BMZ. 
These studies demonstrate that antibodies against a peptide encoded 
for by a region of the 230-kd BP antige!1 cI:?N!,-. seq~ence ~an 
enhance the inflammatory response after epltheltalmJury 111 rabbits. 
MATERIALS AND METHODS 
Immunizations Three female New Zealand white rabbits, ap-
proximately 4 -6 pounds each, were immunized with 2 mg ofP1-2, 
(WTQEPQPLEEKWQHRVVEC) coupled to KLH (Immuno-
dynamics Inc., San Diego, CA) in Freund's complete adjuvant. P1-2 
is encoded for by amino acids 1914 - 1931 of the 230-kD BP Agl, 
with a terminal cystine added to allow conJugatton t~ KLH [13J. 
The animals were then boosted every 2- 3 weeks With 2 mg of 
Pl-2-KLH in Freund's incomplete adjuvant for a total of 4-7 
immunizations. Three control rabbits were immunized with an 
irrelevant synthetic peptide coupled to KLH (CFRPSQQN) in. an 
identical manner. This peptide was derived fr~m the k~own ammo 
acid sequence of gliadin, a wheat storage protem. Rabbits were ble? 
by veni-puncture of e.a r veins and t.he .serum stored at - 70 ·C u.nttl 
used. Antibodies agamst KLH, gltadm, PI-2, and other peptldes 
encoded by the 230-kd DP cDNA were detected i.n rabbit ser~ by 
using enzyme- linked immullosorbent assay as prevIOusly descnbed 
[15J. Pre-immune and immune sera from control and PI-2 -
immunized rabbits were analyzed by mdlrect Immunofluorescence 
using 1 M NaCI split normal human skin and normal rabbit skin as 
substrates and fluorescein-conjugated goat anti-rabbit IgG (Tago 
Inc., Burlingame, CA) [15J. 
UV Irradiation Animals were anesthetized (80 mg of ketamine 
HCI, 2 mg of acepromazine I~aleate, I~ , ~veco Inc., Fort Dodge, 
IA) and their backs clipped With electric cltppers and then shaved. 
Animals were irradiated in pairs (one control and one expenmental) 
using 5 FS-20 bulbs (Westinghouse Corp.) m a portable UVB umt 
(Dermal Contro l, Inc). At 30 cm, the UVB output was 0.321 m W / 
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Table I. IgG Antibodies in Rabbits After Immunization with 
P1-2 and Control Peptides 
Pl-2 Control Peptide 
Immunized Immunized 
2 3 2 3 
KLH >2.0" 1.5 1.4 >2 1.5 1.5 
Gliadin 0 0.01 0 1.6 0.04 1.5 
Pl-2 >2.0 1.5 1.5 0.07 0 0 
P-5 0.11 0.15 0.11 NOb NO ND 
• Net optical density. 492 nanometers on enzyme-linked immunosorbent assay. 
Serum was tested at 1: 100 for KLH and 1: 1000 for gliadin, PI-2. and PS antibody 
assays. 
, ND. not done. 
cm2• Three sites, approximately 2 cm X 2 cm, on the back of tWO 
pairs of rabbits were irradiated on day -1 with 156.' 312, and 
468 mJ/cm2, while protecting the rema1l1der of the rabbit skm. The 
rabbits were then irradiated again on day 0 with 330, 660, and 
990 mJ/cm2• The third pair of rabbits was irradiated with only .tl~e 
higher two doses. After irradiation, rabbit~ were observed for clulI-
cal evidence of inflammation. Cutaneous mflammatlOn was scored 
as follows: O,no erythema; 1+, erythema with a distinct outline.of 
the radiation site but no induration; 2+, distinct erythema With 
induration; and 3+, distinct erythema, with induration and epithe-
lia necrosis. 
In normal, unimmunized rabbits this protocol resulted in no visi-
ble erythema on day 1. On day 2 a distinct erythema without indura-
tion was noted in the sites receiving the higher doses, without any 
induration. Four days post-irradiation aJi sites had returned to nor-
mal, without any evidence of induration or necrosis. . 
Skin biopsies were obtained oflesional skin for routine histol?glc 
studies in two control and two PI-2- immune rabbits and for direct 
immunofluorescence during the inflammatory response and after 
complete healing in all rabbits. Direct i mr~l.Un~fluorescence was 
performed on 4-llm frozen sections of rabbit skin. Antibodies dI-
rected against rabbit C3 (Organon Teknika, :v est ~hester,. PA) and 
rabbit IgG (Tago, Burlingame, CA) were u.tlltzed m the dlrect .un-
munofluorescence studies. Normal, u11lrradlated skm was also blOp-
sied for direct immunofluorescence. 
RESULTS 
Immunization Prior to UYB irradiation all animals were tested 
for the presence of antibodies directed against KLH, gliadin, and the 
synthetic peptide PI-2. IgGdirected against I<!-H was detected III 
the immune sera of all rabbits, whereas IgG dIrected agamst Pl-2 
was found only in the animals immunized with Pl-2 (Table I). IgG 
directed against gliadin was detected only in the animals immunized 
with the control peptide (Table I). None of the anllnals 1I11mu111zed 
with Pl-2 developed antibodies against another, non-overlapping 
synthetic peptide encoded by the 230-kd BP antigen cD NA, P-S 
(Table I) . 
Indirect immunofluorescence of immune sera of rabbits immu-
nized with Pl-2using normal human skin split with 1 M NaCl as a 
substrate revealed the presence of rabbit antibody that bound to the 
epidermal side of human skin in a pattern identical to that seen using 
sera from patients with BP (Fig lA). Rabbi~s immuniz.ed ",,:ith t1~e 
contro l peptide did not have detectable antl-BMZ antibodies (F~g 
IB) . The titers of anti-DMZ antibody against normal human skm 
were 1: 3200, 1: 3200, and 1: 6400 in the three P1-2- immunized 
animals. Indirect immunofluorescence using normal rabbit skin 
split with 1 M NaCI as the substrate also revealed the presence of 
IgG, which bound to the DMZ in linear pattern and localized to the 
epidermal side of the split (Fig 2A,B). Serum from patients with BP 
bound in the same location and pattern on the 1 M NaCI split rabbit 
skin (data not shown). 
Clinical Evaluation After UVB irradiation animals immunized 
with the control peptide developed a mild erythema (grade 1) at 
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Figure 1. Indirect immunofluorescence using 1 M NaCI split normal 
human skin substrate, rabbit sera, and fluoresccinatcd goat anti-rabbit IgG. A 
linear band of rabbit IgG is seen using serum from a rabbit immunized with 
Pl-2 (A), but not with serum from a rabbit immunized with the control 
peptide (B). Bars: A, 31/1m; B, 50 pm. 
24 h at three of eight sites. None of the eight sites developed any 
induration or evidence of epidermal necrosis over the subsequent 
5 d and all had totally resolved within 4-6 d (Fig 3B,D) (Table II). 
In contrast, the animals immunized with Pl-2 all had distinct ery-
thema at all sites of irradiation at 24 h (Fig 3A). By 48 h after UVB 
irradiation, three of eight sites had developed induration along with 
the erythema (grade 2). By 3 to 5 dafter UVB irradiation four sites 
had progressed to show epidermal necrosis and sloughing (grade 3), 
two showed erythema with induration (grade 2), one had erythema 
alone (grade 1), and one site showed no inflammation (Table II) (Fig 
3C) . None of the immunized animals developed any skin lesions 
outside of the area of UVB irradiation. By 14 - 21 days al l sites were 
totally healed. 
Histologic Evaluation Biopsy of lesional, inflamed skin at 24 h 
after UVB irradiation of both control animals examined revealed 
dermal edema, with scattered mononuclear cells within the dermis . 
Sparse polymorphonuclear cells were seen throughout the dermis 
(Fig 4A). In contrasr,lesional skin of both of the P1-2- immunized 
rabbits biopsied 24 h after irradiation revealed an accumulation of 
polymorphonuclear leukocytes and eosinophils at the dermal epi-
dermal junction (Fig 48). Biopsies at day 4 and 7 revealed epidermal 
necrosis and crusting in both P1-2 animals and no abnormalities in 
the skin of the control rabbits. 
Direct Immunofluorescence Studies Direct immunofluores-
cence evaluation of lesional skin from the control and Pl-2 -
A B 
Figure 2. Indirect immunofluorescence using 1 M NaCI split normal rab-
bit skin substrate, rabbit sera, and fluorcsceinatcd goat anti-rabbit IgG. A 
linear band of rabbit IgG is seen on the epidermal basal calls using serum 
from a rabbit immunized with Pl -2 (A) but not using serum from a rabbit 
immunized with the control peptide (B). Bars, 50 11m. 
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immunized rabbits at the time of the inflammatory response to UV 
irradiation (day 1), revealed heavy diffuse deposits ofIgG and C3 in 
the dermis with nO detectable, discreet localization ofIgG or C3 at 
the BMZ. After complete healing of the lesions (14-28 d) direct 
immunofluorescence was performed on the previously irradiated 
sites. A linear band ofIgG was seen at the BMZ in all three animals 
immunized with P1-2 but in none of the control animals (Fig SA). 
Two of three P1-2 animals also had a linear band of C3 present at 
the BMZ, whereas one P1-2-inuTIune animals showed only inter-
mittent granular deposits of C3 at the BMZ (Fig 58). IgG and C3 
were not detected in the healed skin of allY of the three control 
animals (Fig 5C,D). Examination of non- UV-irradiated skin did 
not revea l any specific deposition of either rabbit C3 or IgG in either 
group of animals. 
DISCUSSION 
We have demonstrated that animals with a high-titer antibody 
against a region of the 230-kD BP antigen develop an enhanced 
inflammatory response to UVB irradiation with a neutrophilic and 
eosinophilic infiltrate at the dermal-epidermal junction and the re-
sultant presence of linear deposits of both IgG and C3 at the BMZ. 
This histologic alld immunofluorescence pattern is similar to the 
inflammatory reaction seen in patients with BP and suggests that 
this model may provide a means for further investigation of the 
pathogenesis of DP. 
Although antibodies against the BMZ have been detected in the 
sera and skin of patients with BP their exact role in the pathogenesis 
of this disorder has not been fully characterized. Antibody titers in 
general do not correlate with disease activity [5 ,6]. In addition at-
tempts to elucidate the role of IgG antibodies directed against the 
BMZ in the cutaneous manifestations of BP by the passive transfer 
of antibody to animals have for the most part been unsuccessfu l 
[7,9,10] . Although antibody binding in the skin was demonstrated 
in some monkeys that had been transfused with IgG from patients 
with BP, skin lesions were not noted in these animals [7] . Anhalt 
and co-workers were able to induce epidermal-dermal separation 
with an accompanying inflammatory infiltrate and immunoglobu-
lin deposition when IgG was injected into the cornea of rabbits, but 
not on injection of the IgG into the skin [10]. 
Recently IgG from patients with BP has been shown to react with 
two distinct proteins of the BMZ, both of which have recently been 
cloned and sequenced; the 230-kd BP antigen, BP-AG 1, and the 
180-kd BP antigen [11,13,14,17]. Although sera from most patients 
with BP can im[l1unoprecipitate the 230-kD antigen the role that 
these antibodies play in the pathogenesis ofBP is not known. To try 
and determine which regions of the 230-kD BP antigen may be 
relevant to the pathogenesis of BP we have analyzed several syn-
thetic pep tides encoded for by the 230-kD BP antigen cDNA [15]. 
Thirty-seven percent of patients with BP have IgG antibodies that 
bind P1-2, an 18 -amino acid synthetic peptide (P1-2) encoded for 
by the 230-kd BP antigen cDNA [15]. In addition, rabbits immu-
nized with this peptide develop an IgG antibody that immunopreci-
pitates the 230-kd BP antigen and binds to normal human skin itl 
vitro [15,16]' Finally, affinity-purified IgG directed against P1-2 
from the serum of a patient with BP immnnoprecipitated the 230-
kd BP antigen, demonstrating that this linear epitope is accessible 
on the native BP antigen [15]. These data suggested that this region 
of the 230-kd DP antigen may playa role in the pathogenesis of 
bullous pemphigoid. 
Although rabbits immunized with Pl-2 develop antibodies that 
bind the 230 kD BP antigen expressed in human skin, these animals 
did not show any evidence of ill lIillo antibody binding. We hypoth-
esized that the intracellular localization of the 230-kD BP antigen 
may protect against any antibody binding or antibody-mediated 
damage to the BMZ of the rabbits [16,18,19] . If the epithelium were 
damaged, however, and the 230-kD BP antigen exposed the ani-
mals might develop an inflammatory immune response that could 
mimic BP. In addition, we hypothesized that UVB might provide 
such a mild injUry because UVB and UV A have previously been 
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Figure 3. Clinical results ofUVE irradiation in a control and P1-2- immunized rabbit, irradiated in parallel. The rabbit immunized with P1-2 (A) developed 
a brisk inflammatory response at 24 h with distinct erythema and induration at all three sites. Minimal erythema was seen in the control rabbit (B). At 6 dafter 
UVB irradiation, the rabbit immunized with P1-2 showed epidermal necrosis with sloughing of the epidermis (C), whereas the control rabbit had no evidence 
of inflammation (D) . 
associated with the development of clinical manifestations of BP 
[20-22]. 
Our data supports this hypothesis. Animals immunized with Pl-
2 developed a high-titer IgG that reacted with both normal rabbit 
skin and normal human skin in vitro but did not develop spontaneous 
skin disease or demonstrate binding ofIgG to the BMZ of uninjured 
skin. UVB irradiation, which induced only a mild, short lasting 
erythema in the control rabbits, resulted in an enhanced inflamma-
tory response with the accumulation of polymorphonuclear leuko-
cytes, delayed healing, 'and evidence ofIgG and C3 deposition at the 
BMZ after healing in the rabbits immunized with Pl-2. The mecha-
nism by which th e UVB may expose the 230-kD BP antigen is not 
known. The antigen could be exposed as the result of either direct 
damage to the keratinocytes such as might be induced by other 
forms of epidermal injury. Preliminary studies using cryo-injury 
have shown that animals immunized with Pl-2 had an enhanced 
response to cryo-injury (data not shown). Alternatively, UV light 
may result in th e expressIOn of 230-kD BP antigen on the keratll1o-
cyte cell surface . Although interferon~gamma has ~ee~ sh?wn to 
increase the level of the 230-kD BP antigen mRNA 111 vItro, It IS not 
known if the amount or localization of the 230-kD BP antigen is 
directly affected by UVB, cytokines that occur after UVB irradia-
tion, or other epiderm ally derived factors [23] . 
Although this model system may prove to b~ use~ul in the further 
investigation of the role of the 230-kD BP antigen 111 the pathogen-
esis of BP, several differences between our observations and w hat is 
seen in patients with BP must be addressed. The observation that the 
lesions induced do not result in blister formation in the rabbits , but 
Table II. Inflammatory Response in UVB-Irradiated Sites of 
Pl-2 Immune and Control Rabbits 
P1-2 Immune Rabbits Control Rabbits 
Inflammation Grade Inflammation Grade 
Hours 
Post-UVE 0 2 3 0 2 3 
24-48 O· 5 3 0 5 3 0 0 
72- 110 1 1 2 4 7 1 0 0 
168 4 0 0 4 8 0 0 0 
• Total number of UV-irradiated sites with the specific grade of inflammation (sec 
Materials alld Melhods). A total of eight sites were irradiated on the rabbits in each group. 
rather epidermal necrosis, is different than what is seen in patients 
with BP. This is most likely due to the degree of inflammatory 
infiltrate that develops in the rabbits coupled with the fact that 
rabbit epidermis is only 1- 3 cell layers thick. Furthermore, the lack 
of blister formation may be also due to "anchoring" of the epidermis 
by the large amount of hair present in rabbit skin. We have not been 
able to induce blister formation in rabbits using either graded cryo-
injury or topical psoralens and UV A, suggesting that rabbit skin 
does not blister to the same degree as human skin. 
A second aspect of our findings that is different from that seen in 
patients with BP is that we did not find immunoreactants present 
before the development of skin lesions. This is not entirely unex-
pected because we have immunized our animals with a small 
peptide directed against a region of the BP antigen known to be 
intracellular. Although patients with BP routinely have immuno-
reactants present in normal-appearing skin, it is known that the 
antibody response is directed against a variety of epitopes on the 
230-kD BP antigen and the 180-kD BP antigen and against both 
A B 
Figure 4. Routine histology 24 h after UVB irradiation of the skin of a 
P1-2 - immunized and control rabbits. Skin of control rabbits reveals edema 
and scattered inflammatory cells, with little epidermal change (A). Skin of 
rabbits immunized with Pl-2 show an intense inflammatory infiltrate of 
polymorphonuclear leukocytes and eosinophils within the dermis and at the 
dermal-epidermal junction. Areas of epidermal injury are also present in 
areas of inflammation (B). Hematoxylin and eosin staining. Bars, 42/lm. 
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Figure 5. Direct immunofluorescence of healed sites ofUVB irradiation in 
rabbits immunized with control peptides and P1-2. A linear band of IgG is 
present at the dermal-junction in the rabbit immunized with P1-2 (A) but 
not in the rabbit immunized with the control peptide (C) . A linear band of 
C3 is also seen at the dermal-epidermal junction ofP1 -2- immunized rabbits 
(B) but not control rabbits (D) . Bars: A, 40 J.lm; B, 31 J.lm; C, 25 J.lm; D, 
25J.lm. 
intracellular and extracellular locations [1,2,15,17 -19]. In addi-
tion, the fact that patients with BP have immunoreactants in areas of 
their skin that never develop skin lesions suggests that additional 
factors are necessary for the development of skin lesions [1 ,2]. It is 
not clear what these factors are but our data suggests that we should 
consider the possibility that exposure of intra-cytoplasmic antigens 
may playa role in the development of skin lesions. . 
Finally, additional studies must be performed to address the speCI-
ficity of this reaction. We chose our control peptide from a non-epi-
dermal protein because of the high likelihood that this mechanism 
may be operative with antibodies directed against other cytoplasmIC 
antigens of the skin. Further studies need to be performed to deter-
mine if this will be the case. 
Despite these shortcomings, however, this model system may 
still prove useful for the investigation of the potential role of the 
230-kD BP antigen and the 180-kD BP antigen in the pathogenesis 
of BP. Immunization of rabbits with multiple peptides from differ-
ent regions of theBP antigen(s) may result in a more brisk inflamma-
tory response and a closer mimic of the clinical spectrum of BP. 
These findings suggest that one factor in the pathogenesis of BP 
may involve the exposure of the 230-kD BP antigen from its nor-
mal intracellul ar location, making it accessible to the immune sys-
tem. It is possible that the normal turnover of epidermal basal cells 
may lead to the release of small amounts of the BP antigen, which 
may playa role in the initiation of both the immune response and 
clinical lesions ofBP. Alternatively, it may be that the disease BP is 
initiated by an immune response to an exposed epidermal BMZ 
antigen, perhaps the 180-kD BP antigen, w hich results in epithelial 
injury, leading to exposure of the normally intracellular 230-kD BP 
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antigen. In individuals with an inability to normally regulate their 
immune response to autoantigens, i.e., the elderly, a brisk inflamma-
tory response to the 230-kD BP antigen may develop resulting in 
the clinical manifestations ofBP. In other individuals, perhaps those 
with herpes gestationis, the immune response to the 230-kD anti-
gen does not develop and the disease is more self limited. Although 
this hypothesis is highly speculative, the development of a rabbit 
model and the cloning of both the 230- and 180-kD BP antigens 
p:ovide a mechanism for the investigation of these potential mecha-
111sms. 
In summary, we have demonstrated that rabbits immunized with 
a synthetic peptide encoded for by a linear, intracellular portion of 
the 230-kD BP antigen cDNA develop antibodies to that antigen 
and on exposure to UVB light exhibit an enhanced inflammatory 
response with the deposition of IgG and C3 at the BMZ. Further 
characterization of these findings using other antigens may be a 
means for the further investigation of the pathogenetic role of anti-
bodies directed against different sites on the 230-kD BP antigen as 
well as a way to investigate the interrelationship of antibodies 
against different BP antigens. 
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ANNOUNCEMENT 
The British Society of Investigative Dermatology is awarding three Fellowships for Young 
Investigators in dermatological science or skin biology of £1000 each, as career development 
awards. 
Applicants are requested to forward a one-page summary of their CV including proposed use 
of the fellowship, a 500-word description of their research activities and proposals, and a cover 
letter from their head of department supporting the proposal. 
These three fellowships will be a BSID Young Investigator Award for the United Kingdom, 
a BSID Young Investigator Award for Eastern Europe, and a BSID Young Investigator Award 
for Developing Countries. 
Applications should be submitted to Valerie Brame, Experimental Dermatology Depart-
ment, London Hospital Medical College, 56 Ashfield Street, London E1 2BL. Tel, 
071 377 7724; Fax, 071 247 6509. 
Application deadline is Monday, May 17, 1993. 
ANNOUNCEMENT 
The Annual Meeting of the British Society for Investigative Dermatology will be held 
Sunday - Tuesday, September 19 - 21 , 1993 at the East Midland Conference Centre, University 
of Nottingham. 
Abstracts are invited for oral and poster presentations at this meeting, and awards are made for 
outstanding abstracts/presentations. 
The meeting format includes an overseas guest lecturer talking about "The Molecular Basis 
of Genetic Skin Diseases" and abstracts are particularly invited on this subject. 
In addition, sessions will be dedicated to "Adhesion Molecules" and "Skin Carcinogenesis" 
with expert introductions, and abstracts are also particularly welcome for these topics. Young 
investigators may apply for bursaries to assist attendance at the meeting provided that they are 
co-presenters at the meeting, and there are three BSID Young Investigator Awards (one for the 
UK, one for Eastern Europe, and one for developing countries) from competitive applications . 
Details of how to apply for bursaries and fellowships and how to get abstract forms are 
obtainable from Valerie Brame, Experimental Dermatology Department, London Hospital 
Medical College, 56 Ashfield Street, London E1 2BL. Tel, 071 377 7724; Fax, 071 2476509. 
Abstract deadline is Monday, May 17, 1993. 
